国信证券：小核酸CXO行业景气度持续攀升 迈入临床兑现与商业化加速阶段

Group 1 - The core viewpoint of the articles highlights the rapid growth and commercialization of the small nucleic acid CXO industry, driven by technological breakthroughs and an accelerated commercialization process [1][2] - The small nucleic acid CXO industry is entering a fast development phase, establishing a comprehensive CRDMO service system that includes research and development services, pilot scale-up, and commercial production [1] - The report emphasizes two categories of CXO companies in the small nucleic acid field: those with core technologies such as chemical modification, delivery technology, and conjugation technology, as well as CRO companies with extensive small nucleic acid project experience; and CDMO companies with advanced production capabilities [1] Group 2 - The small nucleic acid drug market is experiencing significant growth globally, with the market size increasing from $2.7 billion in 2019 to $4.6 billion in 2023, reflecting a CAGR of 14.25%; it is projected to reach $45.7 billion by 2033, with a CAGR of 26.08% [2] - A total of 23 small nucleic acid drugs have been approved globally, covering various technological directions such as siRNA, ASO, and aptamers [2] - Although no products have been launched in China yet, the country has a robust research pipeline, second only to the United States, addressing multiple therapeutic areas including hyperlipidemia, hypertension, hepatitis B, kidney diseases, muscle disorders, and obesity; significant collaborations have emerged, such as the $9 billion partnership between WuXi AppTec and Novartis, and a $2 billion platform authorization between Reebio and Boehringer Ingelheim [2]